Editorial Perspectives On Patient Recruitment

71. Patient Centricity And Social Media Are Changing Patient Recruitment 4/18/2019

    Thirty years ago, patient recruitment was a challenge for pharma companies. Today the patient participation rate in trials still hovers around five percent and is not expected to improve anytime soon. Patient recruitment remains a challenge that pharma must work to overcome.  

72. Alzheimer's Disease Trials: Where Do We Go From Here? 4/9/2019

    The Alzheimer’s disease space is not an easy one for pharma companies to navigate. In 2018 alone, Lundbeck, Takeda, Merck, Janssen, AstraZeneca, and Eli Lilly and Company all faced setbacks or poor trial results. Unfortunately, few spaces in the life sciences have fathered failure to the extent that experimental Alzheimer’s drugs have. 

73. 4 Challenges To Overcome In Rare Disease Trials 3/28/2019

    Albireo Pharma is a clinical-stage biopharmaceutical company that was launched in 2008. One of the company’s more promising assets, A4250, is a novel bile acid modulator that has been in development for rare cholestatic liver diseases. The product, which acts locally in the gut, can effectively drain excess bile acids that get stuck in a patient’s liver. In conducting trials with pediatric patients in this space, Albireo faces four challenges common to developers of pediatric rare disease drugs.

74. Fix Patient Recruitment By Learning From Service-Based Companies 3/7/2019

    How is the industry changing its perspective on patient recruitment? Maura Snyder, director of Clinical Insights and Experience at Janssen, shares some of her thoughts on the recruitment challenge and what pharma must do to overcome it. 

75. How Academia, Physicians, And Patient Groups Will Impact Patient Recruitment 2/27/2019

    Thirty years ago, patient recruitment was a challenge for pharma companies. Today the patient participation rate in trials still hovers around five percent and is not expected to improve anytime soon. Mary Rose Keller, VP of Clinical Operations at Heron Therapeutics, shares some of her thoughts on the recruitment challenge and what pharma must do to overcome it. 

76. Clinical Trial Consortium Aims To Eliminate Inefficiency 11/13/2018

    On March 1, 2018, the Partners in Innovation, Education, and Research Consortium™ (PIER) became an LLC in the State of Delaware. The six founding members of PIER (Jefferson Health, Atlantic Health System, Drexel University, Einstein Healthcare Network, Geisinger Health System, and Main Line Health) hope to bring efficiencies and cost reductions to clinical research.

77. Traditional Digital Advertising Rules Don't Apply To Patient Recruitment 10/31/2018

    Syneos Health has released the results of a study conducted to gather real-world patient insights into the effectiveness of digital advertising to assist with clinical trial recruitment.

78. A New Immunotherapy Paradigm: It's Not Just For Cancer Anymore 10/19/2018

    When Bruce Gillis, CEO of EpicGenetics, decided to look into fibromyalgia, he drew blood from 17 patients and analyzed 35 different immune system factors. When compared to a control group, he was astounded by the results. There was a huge disparity between the immune system markers for the 17 patients and those of the control group. That launched his quest for a cure.

79. Rare Disease Trials Require Patient Insights And Input 10/5/2018

    Oftentimes, patients with rare diseases suffer from a myriad of complex symptoms. Unfortunately, given this complexity, rare diseases are not well understood by most general physicians. “With rare diseases, we do not have hundreds or thousands of physicians who are experienced in treating these diseases,” says Dr. Pushkal Garg, Chief Medical Officer at Alnylam Pharmaceuticals. To bring forward meaningful advances for the care of these patients, we must personally speak and listen to them and aggressively integrate their insights.”

80. Clinical Trials: Not Broken, But In Need Of Repair 7/9/2018

    The many challenges sponsors face performing clinical trials led Janet Woodcock, director of the Center for Drug Evaluation and Research at FDA, to remark in 2017 that the clinical trial system is broken. But if that’s the case, how do we uncover the underlying problems and bring all stakeholders together to fix them?